Levetiracetam Injection
Product Images NDC 66298-0447

This text provides information about a Levetiracetam solution, which comes in a 100 mL container with 1000 mg of Levetiracetam per mL in a 0.75% Sodium Chloride Injection solution. It is intended for immediate use after removal from the overwrap and should be infused over a 15-minute period. The solution also contains Sodium Chloride, Glacial Acetic Acid, and is buffered at approximately pH 5.5. It should not be used in series connections, further diluted before use, and should only be used if the solution is clear. The recommended adult dosage is detailed in the package insert. The storage temperature is between 20°C to 25°C and should be discarded after single use. The product is latex-free, non-PVC, and Non-DEHP. The solution is manufactured by Fresenius Kabi in Norway.*

This description is not readable.*

This is a medication called Levetiracetam in 0.75% Sodium Chloride Injection. Each 100 mL contains 1,000 mg of medication, which equates to 10 mg per mL. It is intended for intravenous infusion only and requires a prescription.*

This text provides a comparison of adverse reactions to Levetiracetam (N=769) and Placebo (N=439). It shows the percentage and number of occurrences of various reactions such as asthenia, somnolence, headache, infection, dizziness, pain, and others. The data can be useful for understanding the side effects associated with Levetiracetam compared to a placebo.*

This is a comparison chart showing the percentage of patients in each group for Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. The data indicates that Levetiracetam at both doses was statistically significant compared to the placebo group.*

This is a statistical data set comparing the effectiveness of Levetiracetam at a dosage of 3,000 mg/day with a placebo in a study involving a total of 180 patients and 104 patients, respectively. The data includes percentages of improvement in patients for different groups and notes that the results are statistically significant when compared to the placebo group.*

This is a statistical table showing different percentages in relation to patients taking placebo and levetiracetam. The data includes percentages ranging from 0% to 100%, with the number of patients for each percentage also indicated. The comparison between levetiracetam and placebo is described as "statistically significant."*

This data table shows the percentages of patients in different treatment groups. It includes the placebo group with 95 patients, Levetiracetam 1,000 mg/day group with 97 patients, and Levetiracetam 3,000 mg/day group with 101 patients. It indicates that there is a statistically significant difference between the treatment groups and the placebo.*